News INmune Bio slumps on midstage fail for Alzheimer's drug INmune Bio's bid to develop an Alzheimer's drug with a new mechanism of action has been dented, but the company remains upbeat.
Views & Analysis 3 key trends shaping the immunology market From an increase in sales of interleukin inhibitors to the prevalence of biosimilars, this decade has been an eventful one in the immunology industry.
